FDA 483 - MABXIENCE S.A.U. - April 07, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspection of mAbxience S.A.U. in Garin, Argentina, revealed significant deficiencies in its drug substance manufacturing operations. The firm failed to optimize its manufacturing processes, leading to bioburden control issues, and exhibited inadequately maintained facilities and equipment. Furthermore, the inspection identified shortcomings in environmental control, validation activities, adherence to standard operating procedures, and laboratory controls, indicating a broad lack of control over critical quality systems.
ID · 674ad927-0fa5-4b16-8020-ef29c9106b47